{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:40Z","timestamp":1787026600698,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011698","name":"Chartered Society of Physiotherapy Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, itch is a frequent clinical symptom. Whether mast cells (MCs), eosinophils (Eos) or their mediators play a role in MF-associated itch or disease severity is controversially discussed. Here, we explored the role of MC and Eo numbers in the skin as well as blood levels of their mediators in disease severity and itch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 10 patients with MF and 10 matched control subjects we assessed disease severity, itch, and quality of life impairment using dedicated tools such as the mSWAT, ItchyQoL and DLQI. We analyzed skin biopsies and measured serum levels of tryptase, a mast cell mediator, as well as of the eosinophil products eosinophil cationic protein (ECP) and major basic protein (MBP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The presence of chronic itch, in four of 10 patients, was associated with significantly higher disease severity (mSwat), larger body surface area affected, and stronger QoL impairment (Itchy-Qol, DLQI). Serum levels of tryptase, but not ECP and MBP, were linked with patient-reported disease severity, body surface area affected, and the presence of itch. Three of the four patients with chronic itch, but none of the six patients without, had tryptase levels above &amp;gt;6\u00b5g\/l. Numbers of MCs in the papillary dermis were higher in MF skin lesions then in non-lesional skin of MF patients and skin of healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The MC-mediator tryptase, in MF, is linked to disease activity and impact, most prominently to itch. Our findings call for larger studies that explore the role of MCs, tryptase and other MC mediators as drivers of itch and their role in MF pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.930979","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:38:26Z","timestamp":1660124306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study"],"prefix":"10.3389","volume":"13","author":[{"given":"Dorothea","family":"Terhorst-Molawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ginter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Puhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","volume-title":"Mycosis fungoides - patient information leaflet","author":"Dermatologists","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0789","article-title":"Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat","volume":"90","author":"Meyer","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13261","article-title":"The biomarker landscape in mycosis fungoides and s\u00e9zary syndrome","volume":"26","author":"Dulmage","year":"2017","journal-title":"Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14132","article-title":"Health-related quality of life in patients with cutaneous T-cell lymphoma","volume":"57","author":"Holahan","year":"2018","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with mycosis fungoides and s\u00e9zary syndrome: a systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08992.x","article-title":"Quality of life and psychological distress in patients with cutaneous lymphoma","volume":"160","author":"Sampogna","year":"2009","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1744-8069-4-29","article-title":"Histamine-induced itch and its relationship with pain","volume":"4","author":"Shim","year":"2008","journal-title":"Mol Pain"},{"key":"B10","article-title":"Frontiers in neuroscience pruritus in cutaneous T-cell lymphomas","volume-title":"Itch: Mechanisms and treatment","author":"Misery","year":"2014"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3560","article-title":"Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression","volume":"29","author":"Shimizu","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e31823d921b","article-title":"Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages","volume":"34","author":"Dalton","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9533-9_10","article-title":"The mast cell in innate and adaptive immunity","volume":"716","author":"Shelburne","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/978-1-4419-9533-9_11","article-title":"Mast cells and immunoregulation\/immunomodulation","volume":"716","author":"Tsai","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.348","article-title":"Mast cells have a protumorigenic role in human thyroid cancer","volume":"29","author":"Melillo","year":"2010","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01152.x","article-title":"Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma","volume":"33","author":"Ribatti","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00424","article-title":"Are mast cells MASTers in cancer","volume":"8","author":"Varricchi","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3651","article-title":"Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR\/PRC2-androgen receptor (AR)-MMP9 signals and increased stem\/progenitor cell population","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1230","article-title":"Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression","volume":"16","author":"Strouch","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000087030","article-title":"Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma","volume":"211","author":"Weber","year":"2005","journal-title":"Dermatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9546-3","article-title":"Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases","volume":"107","author":"Rajput","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.4910","article-title":"Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer","volume":"23","author":"Welsh","year":"2005","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00620","article-title":"Mast cell: A multi-functional master cell","volume":"6","author":"Krystel-Whittemore","year":"2015","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.9.1057","article-title":"Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas","volume":"140","author":"Tancr\u00e8de-Bohin","year":"2004","journal-title":"Arch Dermatol"},{"key":"B25","article-title":"Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma","volume":"6","author":"Terada","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2044.2004.03757.x","article-title":"Mast cell tryptase: a review of its physiology and clinical significance","volume":"59","author":"Payne","year":"2004","journal-title":"Anaesthesia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1988.01670060015008","article-title":"The validity and practicality of sun-reactive skin types I through VI","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and s\u00e9zary syndrome: a consensus statement of the international society for cutaneous lymphomas, the united states cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organisation for research and treatment of cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.04.006","article-title":"A pilot quality-of-life instrument for pruritus","volume":"59","author":"Desai","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1544","article-title":"German Version of ItchyQoL: validation and initial clinical findings","volume":"93","author":"Krause","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05090.x","article-title":"Pattern analysis of human cutaneous mast cell populations by total body surface mapping","volume":"148","author":"Weber","year":"2003","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the united states: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02362.x","article-title":"Mycosis fungoides\u2013a retrospective study of 40 cases in Hong Kong","volume":"44","author":"Ku","year":"2005","journal-title":"Int J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01998-7","article-title":"Pruritus and sleep disturbances in patients with psoriasis","volume":"312","author":"Hawro","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18089","article-title":"Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study","volume":"182","author":"Molloy","year":"2020","journal-title":"Br J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810601)47:11<2671::AID-CNCR2820471125>3.0.CO;2-X","article-title":"Prognostic variables in mycosis fungoides","volume":"47","author":"Green","year":"1981","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1338","article-title":"Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides","volume":"90","author":"Yamamoto","year":"1997","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/all.15369","article-title":"Tryptase reference ranges are age-dependent in a large population-based cohort","author":"Slot","year":"2022","journal-title":"Allergy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.11.021","article-title":"Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice","volume":"530","author":"Ui","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","author":"Alvarado","year":"2022","journal-title":"Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:38:33Z","timestamp":1660124313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.930979"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.930979","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"930979"}}